Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sickle cell disease.

George R Buchanan, Michael R DeBaun, Charles T Quinn

    Hematology. American Society of Hematology. Education Program
    |November 25, 2004
    PubMed
    Summary

    Recent advances improve understanding of sickle cell disease (SCD) natural history, including silent stroke and genetic/environmental factors influencing severity. New treatments target hemoglobin S polymerization, red cell dehydration, and endothelial injury for better patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea.

    Blood advances·2026
    Same author

    A New Fetal Hemoglobin-Related Phenotype in Sickle Cell Anemia.

    American journal of hematology·2026
    Same author

    Prevention, Screening, Diagnosis, and Treatment of Iron Deficiency and Iron Deficiency Anemia in Infants, Children, and Adolescents: Clinical Report.

    Pediatrics·2026
    Same author

    NICU to neighborhood: structural drivers shape health inequities for preterm infants.

    Pediatric research·2026
    Same author

    Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

    The New England journal of medicine·2026
    Same author

    Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing Therapies.

    bioRxiv : the preprint server for biology·2026

    Area of Science:

    • Genetics and genomics
    • Hematology
    • Neurology
    • Pharmacology

    Background:

    • Significant progress in understanding sickle cell disease (SCD) natural history and management.
    • Human genome characterization enables study of gene-environment interactions affecting SCD phenotype.
    • Silent stroke and overt stroke affect nearly 40% of children with sickle cell anemia.

    Purpose of the Study:

    • Explore recent advances in SCD knowledge, focusing on silent stroke, disease severity prediction, and pharmacologic treatments.
    • Characterize silent stroke in SCD, comparing it with overt stroke.
    • Review risk factors, prognostic measures, and pharmacologic strategies for SCD management.

    Main Methods:

    • Review of clinical and neuroimaging features of silent and overt stroke in SCD.
    • Analysis of known and newly defined risk factors for SCD severity and survival.
    • Examination of pharmacologic approaches, including hydroxyurea and novel anti-sickling agents.

    Main Results:

    • Silent stroke in SCD has distinct clinical and neuroimaging features but leads to cognitive dysfunction.
    • Risk factors for SCD severity vary, with some known for years and others recently defined.
    • Pharmacologic strategies target hemoglobin S polymerization, red cell dehydration, endothelial injury, and nitric oxide pathways.

    Conclusions:

    • Understanding gene-environment interactions is crucial for managing SCD phenotype and severity.
    • Effective treatments and prevention strategies for silent stroke and other SCD complications are needed.
    • Novel pharmacologic agents and therapeutic approaches show promise for improving SCD outcomes.

    Related Experiment Videos